BASF and Glycosyn sign strategic partnership
German company BASF and US based firm Glycosyn have signed a partnership agreement for the development and commercialization of human milk oligosaccharides (HMOs) for broad use in dietary supplements, functional nutrition, and medical food.
The strategic partnership includes exclusive license of Glycosyn´s patent portfolio for gut health beyond infant nutrition to BASF. The agreement aims to improve gastrointestinal health in adolescents and adults, along with broadening the applications of HMO for further health conditions.
As part of the collaboration and under the exclusive license, BASF will extend its offering of the most abundant HMO, 2’-Fucosyllactose (2’-FL) branded PREBILACTM, to a broad range of customers worldwide. Glycosyn will leverage its scientific expertise and extensive collaboration with the HMO research community to expand the evidence for adult health.